{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:31:45Z","timestamp":1791955905172,"version":"4.3.4"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Pancreatic neuroendocrine tumors (pNETs) are uncommon, comprising 3%\u20137% of pancreatic tumors. With increasing incidence due to advanced imaging techniques, there is a need for detailed characterization of these tumors. This study aims to describe the clinical features, diagnostic evaluations, and pathology characteristics of pNETs in a large cohort from a single tertiary center, and to compare these findings with other larger cohort studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We conducted a retrospective analysis of 866 patients with pNETs who underwent surgical resection at Mayo Clinic, Rochester, from March 2000 to December 2019. Data on demographics, clinical presentation, laboratory tests, imaging, and pathology were extracted and analyzed. Descriptive statistics were used to summarize the data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The cohort had a median age of 57 years. Nonfunctional tumors were much more prevalent (77.5%), with functional tumors primarily being insulinomas (75.9%). Common presenting symptoms included gastrointestinal (45.3%) and nongastrointestinal symptoms (30.7%). Chromogranin A levels were elevated in 57.5% of patients. Imaging revealed enhancing lesions in most cases, with computed tomography scans performed in 90.9% of patients. Endoscopic ultrasound (EUS) identified tumors in 98.1% of cases, with EUS-FNA showing a sensitivity of 82%. Ki-67 index, used in 58.1% of cases, indicated grade 2 tumors as the most common (55.9%). Metastasis was observed in 39.4% of patients at the time of diagnosis, predominantly in the liver.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This study provides a comprehensive description of pNET characteristics in a large surgical cohort. Findings highlight the predominance of nonfunctional tumors and the importance of imaging and EUS in diagnosis. The data can aid in inter-institutional comparisons and enhance understanding of pNETs, contributing to improved patient management and future research.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mpa.0000000000002452","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T15:12:34Z","timestamp":1746198754000},"page":"e423-e429","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Pancreatic Neuroendocrine Tumors\u2014A Descriptive Study of the Presenting Features in a 20-Year Surgical Resection Cohort at a Tertiary Institution"],"prefix":"10.1097","volume":"54","author":[{"given":"Jassimran","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallbera","family":"Gudmundsdottir","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[{"name":"Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Cleary","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreas Surgery, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Kendrick","sequence":"additional","affiliation":[{"name":"Hepatobiliary and Pancreas Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Truty","sequence":"additional","affiliation":[{"name":"Hepatobiliary and Pancreas Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory L.","family":"Smoot","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Nagorney","sequence":"additional","affiliation":[{"name":"Hepatobiliary and Pancreas Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhi Swaroop","family":"Vege","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5]]},"reference":[{"key":"R1-20250502","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/oncolo\/oyac049","article-title":"Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: a SEER database analysis","volume":"27","author":"Sonbol","year":"2022","journal-title":"Oncologist"},{"key":"R2-20250502","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jne.13264","article-title":"Incidence and prevalence of neuroendocrine neoplasms in Norway 1993-2021","volume":"35","author":"Thiis-Evensen","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"100510","DOI":"10.1016\/j.lanepe.2022.100510","article-title":"Incidence and survival of neuroendocrine neoplasia in England 1995-2018: a retrospective, population-based study","volume":"23","author":"White","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"R5-20250502","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.surg.2013.08.002","article-title":"Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors","volume":"155","author":"Crippa","year":"2014","journal-title":"Surgery"},{"key":"R6-20250502","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","article-title":"Pancreatic neuroendocrine tumors (pNETs): incidence, prognosis and recent trend toward improved survival","volume":"19","author":"Halfdanarson","year":"2008","journal-title":"Ann Oncol"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/ajg.2009.747","article-title":"Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases","volume":"105","author":"Zerbi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R8-20250502","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00535-014-0934-2","article-title":"Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis","volume":"50","author":"Ito","year":"2015","journal-title":"J Gastroenterol"},{"key":"R9-20250502","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","article-title":"The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors","volume":"49","author":"Howe","year":"2020","journal-title":"Pancreas"},{"key":"R10-20250502","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000182196","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification","volume":"90","author":"Kl\u00f6ppel","year":"2009","journal-title":"Neuroendocrinology"},{"key":"R11-20250502","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1245\/s10434-014-3769-4","article-title":"Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States","volume":"21","author":"Gratian","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/cancers10090293","article-title":"Visceral obesity and metabolic syndrome are associated with well-differentiated gastroenteropancreatic neuroendocrine tumors","volume":"10","author":"Santos","year":"2018","journal-title":"Cancers (Basel)"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"649496","DOI":"10.3389\/fendo.2021.649496","article-title":"Cardio-metabolic indices and metabolic syndrome as predictors of clinical severity of gastroenteropancreatic neuroendocrine tumors","volume":"12","author":"Barrea","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R14-20250502","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3390\/jcm8091479","article-title":"Disseminated well-differentiated gastro-entero-pancreatic tumors are associated with metabolic syndrome","volume":"8","author":"Santos","year":"2019","journal-title":"J Clin Med"},{"key":"R15-20250502","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/MPA.0000000000000234","article-title":"Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study","volume":"43","author":"Halfdanarson","year":"2014","journal-title":"Pancreas"},{"key":"R16-20250502","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/cen.14727","article-title":"Update on the clinical management of multiple endocrine neoplasia type 1","volume":"97","author":"Pieterman","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R17-20250502","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1159\/000511791","article-title":"Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome\u2014an international consensus statement","volume":"111","author":"Niederle","year":"2021","journal-title":"Neuroendocrinology"},{"key":"R18-20250502","doi-asserted-by":"crossref","first-page":"36073","DOI":"10.1038\/srep36073","article-title":"Risk factors for sporadic pancreatic neuroendocrine tumors: a case-control study","volume":"6","author":"Ben","year":"2016","journal-title":"Sci Rep"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"741096","DOI":"10.3389\/fonc.2021.741096","article-title":"The prognostic and predictive role of chromogranin A in gastroenteropancreatic neuroendocrine tumors\u2014a single-center experience","volume":"11","author":"Tsai","year":"2021","journal-title":"Front Oncol"},{"key":"R20-20250502","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.hpb.2018.09.016","article-title":"Limited role of chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors","volume":"21","author":"Pulvirenti","year":"2019","journal-title":"HPB (Oxford)"},{"key":"R21-20250502","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1472-6823-14-64","article-title":"Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas","volume":"14","author":"Qiao","year":"2014","journal-title":"BMC Endocr Disord"},{"key":"R22-20250502","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.soc.2015.11.007","article-title":"State-of-the-art imaging of pancreatic neuroendocrine tumors","volume":"25","author":"Tamm","year":"2016","journal-title":"Surg Oncol Clin N Am"},{"key":"R23-20250502","doi-asserted-by":"crossref","first-page":"628408","DOI":"10.3389\/fonc.2021.628408","article-title":"Updated trends in imaging practices for pancreatic neuroendocrine tumors (pNETs): a systematic review and meta-analysis to pave the way for standardization in the new era of big data and artificial intelligence","volume":"11","author":"Partouche","year":"2021","journal-title":"Front Oncol"},{"key":"R24-20250502","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.gie.2014.12.031","article-title":"Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis","volume":"81","author":"James","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"R25-20250502","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10620-011-1912-7","article-title":"EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience","volume":"57","author":"Atiq","year":"2012","journal-title":"Dig Dis Sci"},{"key":"R26-20250502","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/jso.26618","article-title":"Multifocality is not associated with worse survival in sporadic pancreatic neuroendocrine tumors","volume":"124","author":"Gudmundsdottir","year":"2021","journal-title":"J Surg Oncol"},{"key":"R27-20250502","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1245\/s10434-017-6140-8","article-title":"Redefining the Ki-67 index stratification for low-grade pancreatic neuroendocrine tumors: improving its prognostic value for recurrence of disease","volume":"25","author":"Lopez-Aguiar","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R28-20250502","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4240\/wjgs.v13.i3.231","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: a clinical snapshot","volume":"13","author":"Fernandez","year":"2021","journal-title":"World J Gastrointest Surg"},{"key":"R29-20250502","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.surg.2018.08.015","article-title":"Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: results from the US Neuroendocrine Tumor Study Group","volume":"165","author":"Zhang","year":"2019","journal-title":"Surgery"},{"key":"R30-20250502","doi-asserted-by":"crossref","first-page":"e2836","DOI":"10.1097\/MD.0000000000002836","article-title":"Differences and similarities in the clinicopathological features of pancreatic neuroendocrine tumors in China and the United States: a multicenter study","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R31-20250502","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/bjs\/znaa141","article-title":"Sporadic non-functioning pancreatic neuroendocrine tumours: multicentre analysis","volume":"108","author":"Ricci","year":"2021","journal-title":"Br J Surg"},{"key":"R32-20250502","doi-asserted-by":"crossref","first-page":"e1284","DOI":"10.1097\/SLA.0000000000005390","article-title":"Grading pancreatic neuroendocrine tumors via endoscopic ultrasound-guided fine needle aspiration: a multi-institutional study","volume":"277","author":"Javed","year":"2022","journal-title":"Ann Surg"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000002452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T15:12:39Z","timestamp":1746198759000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000002452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000002452","relation":{},"ISSN":["1536-4828"],"issn-type":[{"value":"1536-4828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2024-10-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}